Mandate

Vinge advises Zengun Group AB

July 04, 2019 M&A

Vinge has advised Zengun Group AB (publ) in connection with the acquisition of the Zengun Group and in conjunction with a bond issue.

Vinge has advised Zengun Group AB (publ), in connection with the acquisition of the Zengun Group and in conjunction with a bond issue. The construction group Zengun’s founders have, together with the other owners and senior officers, through Zengun Group AB (publ) (the “Company”) repurchased the shares in Zengun Group Holding AB from Segulah Fund V.

In connection with the acquisition, the Company has issued a secured bond in an amount of MSEK 450. The bond, with an interest amount of MSEK 600, is subject to a variable interest rate of STIBOR 3m + 8 per cent and has a final due date in May 2022. The Company has prepared a prospectus which has been approved by and registered at the Swedish Financial Supervisory Authority in accordance with the Swedish Trading in Financial Instruments Act (1991:980) and will apply for listing of the bond on Nasdaq Stockholm.

Vinge’s team primarily consisted of Magnus Pauli, Frida Bergqvist, Lina André, Gabriella Varga, Camilla Andersson, Anna Åhlberg, Josefine Lanker and Jolinn Uhlin.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026